DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Delayed Deutsche Boerse AG 09:33:48 02/07/2024 BST | ||
| 1.82 EUR | 0.00% |
|
| 1 month | +4.60% | ||
| 3 months | +12.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 02/07/24 | 1.82 | 0.00% |
| 01/07/24 | 1.82 | 0.00% |
| 28/06/24 | 1.82 | 0.00% |
| 27/06/24 | 1.82 | 0.00% |
| 26/06/24 | 1.82 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update July 02, 2024 at 09:33 am
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM37QM |
| ISIN | DE000VM37QM9 |
| Date issued | 19/10/2023 |
| Strike | 90 $ |
| Maturity | 20/09/2024 (81 Days) |
| Parity | 10 : 1 |
| Emission price | 0.98 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.82 € |
|---|---|
| Lowest since issue | 0.85 € |
| Spread | 0.01 € |
| Spread % | 0.55% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,005
DKK
Average target price
950.4
DKK
Spread / Average Target
-5.39%
- Stock Market
- Certificates
- Certificat
